OD, Pre-Test: Rheumatoid Arthritis and the Female Patient, Part 2 of 2: Reproductive Health Considerations

1. Rheumatoid Arthritis and the Female Patient: Reproductive Health Considerations

Question Title

Please take a minute to complete this pre-session survey to help ARHP assess the impact of its educational programs. Completing this survey will provide ARHP with an invaluable tool for understanding how health professionals use educational offerings and how ARHP activities might be improved to serve you better.

Question Title

* 1. Your primary professional category (choose the one best response):

Health Professional Educator

Nurse Midwife

Nurse Practitioner

Pharmacist

Physician

Physician Assistant

Registered Nurse

Resident

Student

Other (please specify)

Question Title

* 2. Do you interact with patients?

Yes

Question Title

* 3. Which of the following contraceptives does the CDC’s Medical Eligibility Criteria for Contraceptive Use recommend for a Category 1 patient with rheumatoid arthritis, not on immunosuppressive therapy? (SELECT ALL THAT APPLY)

Combined pill, patch, ring

Copper-IUD

Implant

Injection

LNG-IUD

Progestin-only pill

Question Title

* 4. True or False: Rheumatoid arthritis often improves in women during pregnancy.

True

False

Question Title

* 5. Which of the following pharmaceuticals should lactating women completely avoid? (SELECT ALL THAT APPLY)

Ibuprofen

Prednisone

Leflunomide

Tocilizumab

Tofacitinib

Question Title

* 6. As a result of participating in this activity, I hope to be better able to:

To Receive CME/CE Credit:

Watch the archived webinar.
Complete the post-test evaluation.

Thank you for completing this pre-session questionnaire. Please see the reminder e-mail for complete instructions on how to access the webinar. If you have any questions, please contact education@arhp.org.